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doi:10.1016/j.ejvs.2010.01.018Abstract Objectives: To clear the confusion regarding the relationship between the ‘primary
lymphoedema’ and (truncular) lymphatic malformation (LM); the latter is one of congenital
vascular malformations.
Materials & Methods: A literature review was carried out on the primary lymphoedema either
existing as an independent LM lesion or as a component of the KlippeleTrenaunay syndrome.
Results: The review was able to provide a contemporary guide/conclusion on the definition
and classification, clinical evaluation and clinical management regarding conservative (phys-
ical) therapy, reconstructive surgical therapy and ablative/excisional surgical therapy, for
the primary lymphoedema as an LM.
Conclusions: Primary lymphoedema can be considered as ‘congenital’ since its majority repre-
sents a clinical manifestation of the truncular type of LM arising during the later stages of lym-
phangiogenesis. Such embryological staging information of the LM is critical for proper
management of the primary lymphoedema when it exists with other congenital vascular mal-
formations (KlippeleTrenaunay syndrome).
2. Basic non-invasive to minimally invasive tests will provide an adequate diagnosis and lead
to the correct multidisciplinary, specifically targeted and sequenced treatment strategy.
3. The mainstay of current management of the primary lymphoedema/truncular LM is
complex decongestive therapy; and the reconstructive as well as ablative surgical therapy
remain adjunctive therapies at best.
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Primary Lymphoedema and Lymphatic Malformation 647There has been significant confusion regarding the rela- Such primary lymphoedema that developed as a heredi-
tionship between the ‘primary’ lymphoedema and
lymphatic malformation (LM); further, the definition of
‘primary’ lymphoedema remains controversial.
Many still believe that ‘primary lymphoedema’ and
(truncular) LM are two different disease entities. However,
in our experience, the majority of ‘primary’ lymphoedemas
constitute the clinical manifestation of LM.1,2 Nevertheless,
primary lymphoedema has been managed as a chronic
lymphoedema without consideration of its background as
a congenital vascular malformation (CVM).3,4
For this reason, we decided to review the neglected
aspect of the ‘primary’ lymphoedema as an LM lesion for
a better understanding of what we consider to be the two
sides of the same coin.
Literature review was able to provide a contemporary
guideline on the definition and classification, clinical eval-
uation and clinical management for the primary lymphoe-
dema as an LM.
Primary lymphoedema can be considered as a clinical
manifestation of the truncular type of LM arising during the
later stages of lymphangiogenesis.5,6 Its evaluation should
begin as an LM following a differential diagnosis with
secondary lymphoedema.7,8
Basic non-invasive to minimally invasive tests will
provide the necessary information for an adequate diag-
nosis as an LM9,10 and subsequent management with
complex decongestive therapy as well as reconstructive/
ablative surgery.11,12
Definition and classificationeprimary
lymphoedema as LM
The current concept regarding ‘primary’ lymphoedema
accepts its definition as a clinical manifestation of an LM
developed during the later stage of the
lymphangiogenesis.13,14
However, primary lymphoedema also includes other types
of lymphoedema of an ‘idiopathic’ nature without an identi-
fiable aetiology (e.g., radiation, surgery and infection).15,16
Nonetheless, primary lymphoedema has been consid-
ered to be ‘congenital’ since the great majority is caused
by a congenital defect in the lymph transporting system
including the lymphatic channels and the nodes (e.g.,
aplasia, hypoplasia and hyperplasia).17,18
There are some lymphoedemas that are without clear
relationship to their congenital origin and they do not fit
the conventional concept of a ‘congenital’ condition. Such
an idiopathic condition needs further clarification to reduce
the confusion in terminology.
Similarly, not all primary lymphoedemashaveanatomically
evident ‘truncular’ defects in the lymphatic system. A unique
primary lymphoedema, ‘lymphoedemaedistichiasis
syndrome’19 hasonly oneanomaly, that is, lackof intraluminal
valves of the lymphatic collectors, resulting in lymph reflux.
Another condition with a well-documented genetic defect,
‘hereditary/familial lymphoedema’ also known as Milroy’s
disease,20 doesnothavea grossmacro-structural defect of the
lymphatic vessels. Initial and collecting lymphatics are
present but there is impairment of absorption at the level of
the initial lymphatics, reflecting a functional defect.tary/familial lymphoedema remains in controversy due to
lack of insufficient anatomical defect to support conven-
tional concept for the vascular malformation. That all
lymphoedemas currently grouped as ‘primary’ are genu-
inely primary still remains to be established.
There is also some controversy regarding the current
classification of primary lymphoedemas based on the time of
onset of clinical manifestations: congenital, ‘praecox’ and
‘tarda’ to constitute one spectrum of the disease where an
arbitrary end point of age 35 years is used to separate ‘tarda’
from ‘praecox’. However, there are some conditions classi-
fied as ‘tarda’ that can hardly fit as a ‘primary’ disorder.21,22
By the same token, some congenital lymphoedemas, by
classification, are not true congenital defects but postnatal
obliterations of lymph collectors/lymph nodes, which
simply mimic the congenital/prenatal condition. In a true
sense, these are not a malformation of the lymphatic
system; nonetheless, they are classified as congenital
lymphoedema since they are found at birth.23,24
Hence, it is difficult to claim that ‘primary’ always
reflects ‘congenital’ in the case of lymphoedema.
It has become controversial to define primary lymphoe-
dema on the basis of LM alone. Nevertheless, not only for its
clinical management but also for its prognosis, primary lym-
phoedemashouldbeconsideredasanLMtill provenotherwise.
AnLM is one of the two most common forms of CVMs,1,2 the
other being venous malformation (VM). An LM exists either as
an independent (predominant) lesion or as a combined lesion
with other CVMseVMs,25,26 arterio-venous malformations
(AVMs27,28 and/or capillary malformations (CMs)).29 Such
combined conditions have been classified separately in the
Hamburg Classification30 as haemolymphatic malformations
(HLM)31,32 (Table 1).
The majority of clinical conditions considered as
‘primary’ lymphoedema are due to ‘truncular’ LM arising
during the later stages of lymphangiogenesis.33,34 They
result in hypoplasia, hyperplasia or aplasia of lymph vessels
and/or lymph nodes. Such embryological staging of the LM
is critical for a proper understanding of the LM as one of the
CVMs. A basic knowledge of LM is required whenever
primary lymphoedema is believed to underlie limb swelling.
The LM is further classified into two subgroups based on the
embryological stage when developmental arrest occurred.
‘Extratruncular’ lesions develop at an earlier stage of
embryogenesisand‘truncular’ lesionsoriginateata later stage.
The truncular LM is better known as primary lymphoe-
dema while extratruncular lesions are known as cystic/
cavernous lymphangiomas.18
These two different types of LMs resulting from different
embryologic stages are often mistakenly identified as two
different and unrelated disease entities. However, these
lesions are inseparable and often co-exist, affecting each
other profoundly.
A clear understanding of primary lymphoedema as
a truncular type of LM is necessary to establish its
contemporary classification as a vascular malformation.
Extratruncular LM lesions
Extratruncular lesions are the result of premature embryonic
tissue that fails to involute and remains in the condition of
Table 1 Hamburg Classification of Congenital Vascular Malformation (CVM), modified.a,b
Main classfication based on its predominent vascular component:
Predominantly arterial defects
Predominantly venous defects
Predominantly AV (arterio-venous) shunting defects
Predominantly lymphatic defects
Predominantly capillary malformation
Combined vascular defects
Subclassification based on its embryological stage of the defect:
Extratruncular forms - developmental arrest at the earlier stages of embryonal life:
Diffuse, infiltrating
Limited, localized
Truncular forms - developmental arrest at the later stages of embryonal life:
Aplasia or obstruction
Hypoplasia; Aplasia; Hyperplasia
Stenosis; Membrane; Congenital spur
Dilatation
Localized (aneurysm)
Diffuse (ectasia)
a Both extratruncular and truncular forms may exist together in same vascular malformation; may be combined with other various
malformations (e.g. capillary, arterial, AV shunting, venous, hemolymphatic and/or lymphatic); and/or may exist with hemangioma.
b Based on the consensus on the CVM classification through the international workshop in Hamburg, Germany, 1988, which was upheld
by subsequently founded ISSVA (International Society for Vascular Anomaly).
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ular stage.35,36 The cystic/cavernous lymphangioma is
a remnant of embryonic tissue that developed before the
lymphatic/vascular trunks were formed. This gives it the
designation of a pretruncal embryonic lesion.
Extratruncular lesions maintain the unique embryonic
characteristics of the mesenchymal cells that grow when
provoked or stimulated by various conditions such as trauma,
menarche, pregnancy, surgery or hormonal changes. They
will never disappear and will remain throughout adult life
and because of their origin, will continue to grow.
Extratruncular lesions present as diffuse infiltrating
conditions that exert mechanical pressure on surrounding
tissues and organs, including nerves and muscles (e.g.,
cystic hygroma). Such lesions usually form a closed system
independent of normal lymph-conducting pathways without
direct communication although they could co-exist with
lymphoedema-causing truncular lesions.
Truncular LM lesions
By contrast, truncular lesions are the result of develop-
mental arrest occurring at later stages of foetal develop-
ment during the formation of the lymphatic trunks, vessels
and nodes long after the reticular stages of vascular
development have ceased.35,36 These are termed post-
truncal foetal lesions.
Truncular lesions, therefore, no longer have the evolu-
tional power to grow or recur. They have lost the embryonic
characteristics of mesenchymal cells and have no risk of
recurrence, but have a significant lymphodynamic impact
on the involved lymph-transport system.
Truncular lesions occur in various clinical conditions as
the result of an incomplete development of the axial or
truncal lymphatic vessels. Depending on the severity orextent of the abnormality occurring during the last matu-
ration period of the lymphatic system, various conditions,
such as aplasia, hypoplasia or hyperplasia of lymphatic
vessels and/or lymph nodes, may result. These may be
clinically manifest as obstruction or dilatation. When the
endoluminal valves are absent or defective, reflux becomes
the most important clinical manifestation.
Clinical evaluationeprimary lymphoedema
as LM
The evaluation of primary lymphoedema as one of the
chronic lymphoedemas4,5 should start with a differential
diagnosis with secondary lymphoedema and its various
causes e infection, surgery and radiation e and then
proceed to its full evaluation as a truncular LM followed by
its proper staging as chronic lymphoedema.37,38
Appropriate periodical clinical staging of the lymphoe-
dema status is essential for the proper selection of the
therapy regimen;7,38 depending upon its stage, timely
addition of supplemental therapy (e.g., surgical therapy)
can be instituted to improve its management.39,40 Detailed
information on how to assess the clinical staging is well-
documented elsewhere by many, including the Interna-
tional Society of Lymphology (ISL).37
The evaluation of primary lymphoedema as an LM should
start with basic evaluation of the CVM as a whole and
include consideration of the potential risk of other
combined CVM lesions (e.g., KlippeleTrenaunay
syndrome).31,32 In such a circumstance, the evaluation of
extratruncular LM should be included when the clinical
findings alone cannot rule out its co-existence.
Clinical evaluation should proceed with complete clinical
history, including family history and physical examination.
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of non-to-minimally invasive tests can be selected to confirm
the clinical impression as explained in detail else-
where.1,2,5,12,18,41e44
Usually, a combination of the lymphoscintigraphy (LSG)
and Duplex ultrasonography will provide the basic infor-
mation necessary to insure an adequate diagnosis and lead
to the correct multidisciplinary treatment strategy for the
primary lymphoedema by independent truncular LM alone.
However, a few specific tests41e44 can be added as options
when more detailed information is mandated to rule in/out
other CVMs involved together.
Radionuclide LSG45,46 is the most essential test and
remains the ‘gold standard’ for the evaluation of
lymphatic function. Periodic appraisal of the LSG is
preferred for adequate laboratory staging to supplement
clinical staging necessary for better clinical management,
in our experience. However, its cost/benefit value remains
debatable.
Together with LSG, Duplex ultrasonography43,47 for
evaluation of venous function is indicated in every case of
lymphoedema. This is because accurate assessment of
venous function is essential to rule out accompanying
abnormal venous conditions that often act as predisposing
factors for the deterioration of the LM condition. One of the
best examples of this is aplasia/hypoplasia of the ilio-
femoral venous system found in 4% of CVMs.48
Duplex ultrasonography is also able to provide more
information in lymphoedematous limbs, such as location
and evidence of fluid collections, node dilation/atresia and
tissue alterations/echogenicity.
Magnetic resonance imaging44 is not mandated for the
primary lymphoedema as a routine but it is essential for the
basic assessment of extratruncular LM involved; however,
its intrinsic proprieties as a lymphatic vessel/node imaging
include its ability to differentiate congenital abnormalities
of lymphatic/organ/tissue in lymphoedematous patients,
hence orientating towards LM.
Many other tests suggested for the evaluation of the
CVMs remain as optional and may be added when indi-
cated.1,2,5,10,14 For example, segmental bio-impedance
analysis has gained popularity and scientific validation in
lymphoedema assessment in general and it could be added
among diagnostic methods as an option.
Invasive tests are necessary on some occasions to
provide more information for an accurate differential
diagnosis. However, these tests should be considered as
road-mapping for subsequent therapy.
Percutaneous lymphangiography using regular contrast
material to the extratruncular LM lesion by a direct punc-
ture technique is seldom needed to refine the extra-
truncular LM-related diagnosis and can be deferred until
needed to verify the extent/severity of the lymphangioma
lesion for subsequent therapy.
Conventional oil-contrast lymphangiography has been
abandoned due to its potential risk of damage to the
lymph vessels by the oil contrast agent. However, it is still
useful when the benefit outweighs the risk in selected
patients with chylous dysplasia and gravitational reflux
disorders to better define the extension of the pathologic
alterations and sites of lymphatic and chylous leakage.
However, conventional lymphography using the patentblue dye is still popularly used by lymphatic surgeons as
a road map to handle either truncular or extratruncular
LM lesion safely.
Fine-needle aspiration biopsy with cytological examina-
tion should substitute excisional biopsy of regional lymph
nodes that often aggravates the condition while providing
limited information on the cause of lymphoedema.
Diagnosis should aim at proper clinical and laboratory
staging38 of the disease and should include periodical
assessment of clinical and sub-clinical infections in the
early and latent stages for effective prevention of various
conditions such as tinea pedis. Diagnostic evaluation should
include appropriate assessment of patient compliance since
the outcome of successful management is largely depen-
dent on this crucial factor.
Lymphoedema in children can be a part of the syndrome
if there are other concomitant phenotypic abnormalities.
However, diagnosis has to be made mainly on the basis of
careful personal and family history and physical examina-
tion during the initial phase.
Further investigations may include appropriate genetic
testing for the detection of specific hereditary syndromes
with discrete gene mutation (e.g., FOXC2 for lymphoede-
maedistichiasis and vascular endothelial growth factor
receptor (VEGFR)-3 for Milroy’s disease).49,50 Genetic
testing combined with phenotypic descriptions may provide
a better understanding of familial lymphangiodysplastic
syndromes and other congenital/geneticedysmorphogenic
disorders, which can manifest as lymphoedema.
Clinical evaluation with periodical interval should include
proper documentation of the staging of lymphoedema (e.g.,
ISL Stage 1 through III),13,37 severity of oedema (volume)
(mild e moderate e severe), proper description of the skin
and subcutaneous tissue changes and functional assessment
of the affected limb. A thorough assessment of the gathered
information will be able to guide precise management deci-
sions and selection of therapeutic options.
Clinical managementeprimary lymphoedema
as LM
When truncular LM (primary lymphoedema) and extra-
truncular LM lesions co-exist, extratruncular LM lesions
(i.e., lymphangiomas) should have a treatment priority.
The extratruncular lesion often accelerates the deteriora-
tion of the truncular lesion by increasing the lymphatic
burden to an already jeopardised lymphatic system. When
the LM lesions co-exist with other CVMs, the treatment
priority should generally be given to others such as VM or
AVM if they are clinically significant ‘major’ lesions.51,52
The detailed information on the management of extra-
truncular LM will be referenced in other publications.1,2,18
A. Conservative (physical) therapy
Contemporary management of truncular LM aims to control
its clinical manifestation as primary lymphoedema.
Complex decongestive therapy (CDT) is now the treat-
ment of choice regardless of the condition/clinical stage. It
consists of exercise/movement, manual lymphatic drainage
(MLD) and compression (bandaging, garments) therapy, in
650 B.B. Lee, J.L. Villavicencioaddition to basic skin care, education for risk reduction of
infections and trauma.53,54
However, CDT is a strategy to control the oedema and
does not result in ‘cure’. CDT generally is effective only
during the treatment programme period. To maintain long-
term control often means continuous patient commitment
and requires a lifetime pledge.
MLD is likely to decompress lymphatic congestion
effectively by physiologic stimulation of a poorly func-
tioning lymph transporting system through the opening of
collateral lymph pathways. MLD-based CDT, with or without
combination with sequential intermittent pneumatic
compression (SIPC) therapy, is still most effective for the
truncular LM lesions, whether alone or combined with
extratruncular LM lesions.
SIPC using pumping devices is particularly useful in those
cases that are treated by passive physical therapy (elderly,
patients in bed, with serious disabilities, etc.) in whom
spontaneous/isotonic physical exercise is not possible or is
highly compromised.55,56
However, there is a significant concern regarding the
possible negative side effects by pressotherapy, resulting in
tissue fibrosis at the root of the limb by the stagnating
proteins.Table 2 Contemporary Indications for the Surgical
Treatment of Primary Lymphedema.
Indications for Reconstructive Surgery:
1) Failure to respond to proper care at earlier clinical
stage (stage I or IIa).
2) Progress of the disease to advanced stages such as
from stage I to stage II or stage II to III despite proper
treatment.
3) Chylous-reflux combined with extremity lymphedema.
Indications for ablative/excisional Surgery:
1) Failure to implement proper care at clinical stage
III or IVa (end stage) with increasing technical
difficulty to wrap the limb adequately.
2) Progress of the disease to the end stages in spite
of maximum available treatment.
3) Increased frequency and/or severity of local
and/or systemic episodes of sepsis.
a New staging method proposed by Lee & Bergan (Lymphology
38 (3):122-129, 2005).B. Surgical therapyereconstructive surgery
The goal of reconstructive surgery for the primary lym-
phoedema is identical to that for the secondary lymphoe-
dema, aiming at the repair of damaged lymph-transport
system to restore the lymphatic function. There are several
methods: lympho-venous or lympho-lymphatic bypass
anastomosis, lympho-lymphatic segmental interposition
and free lymph node transplantation.57e60 They are more
theoretically sound than CDT with a possible chance of
‘cure’ in early stage lymphoedema.
Nevertheless, the truncular LMs have an extremely
variable number and condition of lymph vessels and lymph
nodes as exemplified by the various forms of dysplasias,
such as lymphangiodysplasia, lymphadenodysplasia and
lymphangioadenodysplasia (Papendieck’s classification).61
Candidates for reconstruction are, therefore, rare
among the primary lymphoedemas due to the variable
anatomy, although some have reported different findings.62
Surgery outcomes are also variable, but generally not as
successful as those of secondary lymphoedema patients
that have surgically correctable lesions along the major
lymphatics/collectors, in our experience.4e6
Furthermore, the surgical lymphatic reconstruction is
generally time-consuming and requires dedication and
expertise in the use of microsurgical techniques. This is
especially true in primary lymphoedema caused by trun-
cular LM due to its anatomical complexity.61
In the majority of the cases, CDT provides satisfactory
results in the management of lymphoedema in its early
stage. Lymphatic reconstruction is, therefore, selected only
when CDT-based therapy fails to prevent the progress of
lymphoedema and where there is clear risk of further
damage to the lymphatic system. The recruitment of the
ideal candidate for reconstructive surgery in the early stages
of lymphoedema, while dysfunction is reversible, is ofoutmost importance due to the risk of losing critical numbers
of lymph vessels available for surgical reconstruction.
Therefore, we consider reconstructive surgery as an
adjunctive therapy to a CDT-oriented treatment regimen
with specific indication (Table 2). Together with CDT, both
methods are mutually complementary and remain useful.
However, there have been considerable doubts
regarding CDT’s real benefit due to limited scientific
evidence and the lack of sound data, especially for long-
term follow-up scientific studies; similarly, a lack of
reproducibility of the outcomes presented by the very few
teams mandates a well-balanced double-blind multicentre
prospective study.
C. Surgical therapyeablative/excisional surgery
Various methods introduced throughout the decades (e.g.,
Charles procedure) have been known for severe morbidity
and poor long-term results. Recently, the original tech-
niques were reintroduced aiming to reduce its morbidity
(e.g., modified Auchincloss/Homans procedure).63e66 Once
the lymphoedema advances to an irreversible stage, it has
a tendency to progress steadily despite aggressive CDT with
or without complementary compression therapy.39,67
When chronic lymphoedema reaches the later/end stage
(stage III and IV), most of the normal tissues become
fibrosclerotic and present technical difficulties for efficient
CDT application. Such a condition increases a tendency for
recurrent local and/or systemic episodes of sepsis.39
An excisional surgery becomes a measure of last resort in
such a case once the multidisciplinary team admits its
failure to arrest progress towards the end stages with CDT
and with evidence of steady deterioration despite
maximum treatment (Table 2).
However, without adequate postoperative CDT, exci-
sional surgery alone cannot maintain the initial success of
surgery and will most probably fail in the long-term.67
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Lipectomy
Liposuction is a newly proposed method to reduce the
morbidity involved in the traditional excisional tech-
niques; rather, liposuction was designed to obliterate the
epifascial compartment by a selective removal of exces-
sive adipose tissue alone, which developed by secondary
lymphoedema of the upper limb, following the mastec-
tomy.68 However, its efficacy has not been proven for the
primary lymphoedema, which has entirely different
background as a truncular LM. But when the primary
lymphoedema reaches the end stage with no risk of
collateral damage to the viable lymph vessels by the
suction, entire tissues become fibrosclerotic with a very
limited amount of fat tissue available for the liposuction
procedure to improve local swelling. Other than publica-
tions on the ‘secondary’ lymphoedema following radical
mastectomy, this method lacks scientific merit with regard
to the primary lymphoedema.
Prospecteprimary lymphoedema as LM
During the past few decades, advanced technology has
brought new information to the CVMs, especially in the
genetic aspect of primary lymphoedema of LM origin.
Recently, basic investigations of the lymphatic circula-
tion have led to identification of key molecular processes
that promote normal vascular development and differen-
tiation in this vital circulatory system. These developments
have conducted further to the identification of critical
endothelial markers that have advanced the study of
human lymphatic disease.
Delineation of the genetic and molecular abnormalities
of several primary, heritable lymphatic disorders, including
VEGFR-3 for Milroy disease, FOXC2 for lymphoedemaedis-
tichiasis syndrome and SOX18 for lymphoedema-
hypotrichosis, has provided a better understanding of
familial lymphangiodysplastic syndromes and other
congenital/geneticedysmorphogenic disorders, which can
manifest as primary lymphoedema.49,50,69
The appropriate identification of the gene defects to be
corrected heralds a new era of gene therapy in lymphatic
vascular diseases.70,71
Therapeutic implementation of gene modification during
embryonic development and also to the abnormal function
in adults will become the ‘ultimate’ dream/goal of gene
therapy to correct the mechanisms of LM.
Summary
1. Primary lymphoedema can be considered to be
‘congenital’ since the majority is caused by congenital
defects in the lymph transporting system including both
the lymphatic channels and the nodes (e.g., aplasia,
hypoplasia and hyperplasia). However, it remains to be
proven that all lymphoedemas currently grouped as
‘primary’ are appropriately classified.
2. The majority of primary lymphoedemas represents
a clinical manifestation of the truncular type of LMarising during the later stages of lymphangiogenesis.
Contemporary classification, including embryological
staging as one of the vascular malformations, is
mandated for proper diagnosis and management of the
primary lymphoedema as truncular LM in conjunction
with other CVMs.
3. Subsequent to differential diagnosis with secondary
lymphoedema, evaluation of primary lymphoedema
should start as an LM. Basic non-invasive to minimally
invasive tests will provide basic information necessary
to insure an adequate diagnosis and lead to the correct
multidisciplinary, specifically targeted and sequenced
treatment strategy.
4. The mainstay of current management of the primary
lymphoedema/truncular LM is CDT, and reconstructive/
ablative surgical therapy remains an adjunctive therapy
at best.
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